Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zephapharm Ltd. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This indicates a focused prosecution strategy, likely centered on a specific pharmaceutical or biological invention. The limited volume of active matters suggests that the company is prioritizing the protection of a core asset in its current patent filings.
The company's active prosecution is limited to a distinct examiner and 1 distinct art unit. This concentration suggests that the subject matter is being evaluated by a specialized technical group at the patent office. SUN JAE YOO is the busiest examiner for the portfolio, currently handling the busiest examiner pending office action. This examiner is the only one currently reviewing Zephapharm Ltd.'s patent applications, which allows for a more consistent and focused technical dialogue.
With only 1 pending office action, the administrative burden on the company is minimal. The prosecution team can focus entirely on the specific requirements of the distinct art unit involved. The outcome of the current interaction with SUN JAE YOO will be the primary factor in the company's immediate success within the Biotechnology & Pharmaceuticals sector, requiring a response that is highly tailored to this examiner's specific technical standards.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430781 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | YOO, SUN JAE | 28d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17430781 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | YOO, SUN JAE | 1621 | §102§103 | Non-Final OA | 28d | Pending | Aug 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZephapharm Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sun Jae Yoo has the most, with 1 of Zephapharm Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
